Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy
文献类型：期刊论文
| 作者 | Tian Ye3; Sun Changyu3; Zhang Limeng2; Pan Yuan3 |
| 刊名 | Cancer Biology & Medicine
 |
| 出版日期 | 2018 |
| 卷号 | 15 |
| 关键词 | MiRNA-106a NSCLC cisplatin gemcitabine chemotherapy resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| ISSN号 | 2095-3941 |
| 其他题名 | Clinical significance of miRNA-106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy |
| 英文摘要 | Objective: Research has demonstrated that microRNA (miR)-106a is related to cisplatin resistance. We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer (NSCLC) and their sensitivity to chemotherapy by cisplatin combined with gemcitabine. Methods: Eighty-five NSCLC patients, who completed four cycles of gemcitabine and cisplatin chemotherapy, volunteered for this study and their serum samples were collected. Serum samples from 60 healthy subjects were used as controls. Real-time quantitative polymerase chain reaction (real-time qPCR) was used to quantify the level of miR-106a in the serum. Demographic and survival data of these patients were collected for the analysis. Results: The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects ( P < 0.001). The expression of miR-106a was not correlated with patients' gender, age, tumor size, lymphatic metastasis, and pathological types; but was correlated with patients' tumor staging ( P = 0.003). After chemotherapy, serum miR-106a expression decreased in patients. The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group. Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis. The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group. Conclusions: High expression of miR-106a may be involved in the development of NSCLC. MiR-106a has significance in the prognosis of NSCLC. The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy. |
| 语种 | 英语 |
| CSCD记录号 | CSCD:6272315 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/106190]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Int Personalized Canc Ctr, Tianjin 300450, Peoples R China 2.中国科学院合肥物质科学研究院肿瘤医院 3.中国科学院大气物理研究所 |
| 推荐引用方式 GB/T 7714 | Tian Ye,Sun Changyu,Zhang Limeng,et al. Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy[J]. Cancer Biology & Medicine,2018,15. |
| APA | Tian Ye,Sun Changyu,Zhang Limeng,&Pan Yuan.(2018).Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy.Cancer Biology & Medicine,15. |
| MLA | Tian Ye,et al."Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy".Cancer Biology & Medicine 15(2018). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。